EGFR and non-small cell lung carcinoma: Another study evaluating osimertinib with or without chemotherapy versus chemotherapy alone as neoadjuvant therapy in patients with resectable EGFR‐mutated NSCLC NeoADAURA (NCT04351555) is ongoing.